A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(24 sites)

United States

Site 0264, Aurora, Colorado

Site 0104, Boston, Massachusetts

Site 0111, St Louis, Missouri

Site 0173, New York, New York

Site 0259, Durham, North Carolina

Site 0191, Providence, Rhode Island

Site 0196, Nashville, Tennessee

Site 0103, Houston, Texas

Australia

Site 2707, South Brisbane, Queensland

Site 2708, Sunshine Coast, Queensland

Site 2709, Adelaide, South Australia

Site 2716, Melbourne, Victoria

Site 2706, Melbourne, Victoria

Site 2705, Nedlands, Western Australia

Bosnia and Herzegovina

Site 1001, Banja Luka

Site 1002, Sarajevo

Site 1003, Tuzla

Bulgaria

Site 1202, Panagyurishte

Site 1201, Sofia

Georgia

Site 1401, Tbilisi

Serbia

Site 1902, Belgrade

South Korea

Site 2901, Busan

Site 2903, Seoul

Site 2904, Seoul